Cancer drug developer AUM Biosciences raises $27m from Everlife, SPRIM

Cancer drug developer AUM Biosciences raises $27m from Everlife, SPRIM

12 October, 2021

AUM biosciences biotech life sciences

Printed by Unregistered user on Sun, 24 Aug 2025 00:19:17 GMT

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Subscribe to Newsletter

You may also like

SG-based AUM Biosciences raises $1.5m in seed funding to develop affordable oncology drugs

SG-based Engine Biosciences raises $43m Series A led by Polaris Partners

Read more from Singapore

Beyond the Buyout: PE buyouts in India aren’t retreating, they’re evolving

Wealthy investors in Asia seek more crypto in portfolios